Skip to content
Sign up to receive our free weekday morning edition, and you'll never miss a scoop.
House passage would amount to a symbolic rebuke of Trump’s actions since the Senate is expected to again defeat a similar war powers resolution. 

Russia sanctions effort has a tariff problem

A push from defense hawks to slap new sanctions on Russia has run into another politically toxic snag: tariffs.

President Donald Trump has been reluctant to bless a congressional effort on sanctions, which has overwhelming bipartisan support. The White House has already forced revisions that would expand the president’s tariff authority. This is now threatening Democratic support.

“We can do things that target Russia,” Rep. Gregory Meeks (D-N.Y.), ranking member of the House Foreign Affairs Committee, told us. “Tariffs turn out to really just be a tax [on] the American people.”

The tariff changes set off alarms for key House and Senate Democrats, who oppose the administration’s trade wars and don’t want to give any ammunition to the White House’s Supreme Court case.

Meeks and Reps. Brian Fitzpatrick (R-Pa.) and Steny Hoyer (D-Md.) met Wednesday and are likely to strip out all of the tariff language from the House bill and boost the sanctions portion instead. The group expects to settle on consensus language this morning and use it to get moving on a discharge petition.

But Sen. Lindsey Graham (R-S.C.), who is leading the Russia sanctions effort in the Senate, isn’t backing down.

Since first introducing the bipartisan sanctions bill, Graham has beefed up authorities for the administration to levy tariffs on third-party countries that buy Russian oil.

Now Graham wants to keep the tariff language, according to sources familiar with the discussions. This leaves the push in a fragile spot. And it means that even if Trump comes around, the proposal still may not be able to win congressional approval and reach his desk.

Presented by AstraZeneca

The 340B program was created to help patients. Instead, it’s helping hospitals earn massive profits. The 340B Rebate Model Pilot uses rapid verification of existing data to prevent duplicate discounts, strengthening program transparency and efficiency. Urge HHS to implement the Rebate Model Pilot and ensure 340B functions as intended. Get the facts.

Editorial photos provided by Getty Images. Political ads courtesy of AdImpact.

Presented by AstraZeneca

The 340B program is supposed to help vulnerable patients—but without strong safeguards, it’s siphoning away funds that could be used for free and charitable medicine. The 340B Rebate Model Pilot improves program integrity, preventing duplicate discounts and strengthening accountability. Urge HHS to implement the pilot today. Learn why it matters.

Welcome to Punchbowl News AM! We're glad to have you here.

Want to get more of what you need? Share a bit more about yourself to help us tailor your reader experience.

Thank you for signing up!

Thank you for signing up!

 

We have sent you a confirmation email. Please follow the provided instructions to complete your sign-up.

Thank you for confirming! You are now subscribed to the Punchbowl News AM list.

You're subscribed! Welcome to the community.